Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 4

Results For "clinical-development"

615 News Found

EMA accepts filing for Teva and Medincell’s long-acting schizophrenia treatment candidate
News | May 25, 2026

EMA accepts filing for Teva and Medincell’s long-acting schizophrenia treatment candidate

If approved, TEV-‘749 would mark a shift toward long-acting care aimed at improving treatment adherence in real-world settings


EU regulator backs Allergan Aesthetics’ Boey in key step toward approval
Drug Approval | May 25, 2026

EU regulator backs Allergan Aesthetics’ Boey in key step toward approval

The decision marks a key step in the centralized EU review process


WACKER launches contract research services to accelerate next-gen RNA & DNA therapies
R&D | May 23, 2026

WACKER launches contract research services to accelerate next-gen RNA & DNA therapies

The new CRS offering is delivered from WACKER’s Biotechnology Center in Munich


Sun Pharma reports FY26 revenue of Rs. 58,220 crore, net profit at Rs. 11,479 crore
News | May 22, 2026

Sun Pharma reports FY26 revenue of Rs. 58,220 crore, net profit at Rs. 11,479 crore

Q4FY26 revenue rises 13.6% to Rs. 14,560 crore; quarterly net profit jumps 26.2% to Rs. 2,714 crore driven by India business and Innovative Medicines growth


Pfizer advances next-gen pneumococcal vaccine after strong Phase 2 infant data
Clinical Trials | May 21, 2026

Pfizer advances next-gen pneumococcal vaccine after strong Phase 2 infant data

Pfizer says the broader dataset across all 25 serotypes strengthens confidence that the program can meet non-inferiority thresholds in its upcoming Phase 3 pediatric trials


Bristol Myers Squibb & Anthropic redraw biopharma with Claude-powered enterprise AI
Digitisation | May 21, 2026

Bristol Myers Squibb & Anthropic redraw biopharma with Claude-powered enterprise AI

BMS is moving beyond conversational AI into what it describes as “agentic” systems


Bayer’s NUBEQA combo shows 71% drop in risk of progression or death in prostate cancer trial
Clinical Trials | May 19, 2026

Bayer’s NUBEQA combo shows 71% drop in risk of progression or death in prostate cancer trial

Despite the strong results, investigators cautioned that the study has limitations, including its open-label Phase II design, lack of randomization, and reliance on a historical external control arm


FDA expands Enhertu use in early HER2-positive breast cancer
Drug Approval | May 19, 2026

FDA expands Enhertu use in early HER2-positive breast cancer

AstraZeneca highlighted the move as a major step toward earlier intervention in curable disease


Kotak Alts invests Rs. 200 million in Cellogen Therapeutics
Biopharma | May 18, 2026

Kotak Alts invests Rs. 200 million in Cellogen Therapeutics

Funding to support clinical development, gene therapy pipeline expansion and GMP manufacturing capabilities


Merck to showcase 100+ oncology studies at 2026 ASCO meeting
R&D | May 14, 2026

Merck to showcase 100+ oncology studies at 2026 ASCO meeting

Highlighting KEYTRUDA & expanding cancer pipeline